TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02991001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodissection
Description: Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
Study: NCT02974439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc Tablets 5mg
Description: Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
Study: NCT04080453

Intervention type: OTHER
Intervention: Septic shock
Description: Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
Study: NCT02991001

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound-guided injection
Description: Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Study: NCT04080453

Intervention type: OTHER
Intervention: Systemic Inflammatory Response Syndrome
Description: Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
Study: NCT05441644

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral index
Description: A new placemewnt to monitor intraoperative BIS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: A new placemewnt to monitor intraoperative BIS
Study: NCT00944515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet or syrup 3 days/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: azithromycin 3 days/week
Study: NCT03908957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga68-Dolacga Injection
Description: Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
Study: NCT04716335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT
Description: DMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harmine
Description: Harmine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harmine
Description: Harmine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Harmine)
Description: Placebo for Harmine
Study: NCT02991001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study: NCT03685604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHX disinfection
Description: CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
Study: NCT04716335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (DMT)
Description: Placebo for DMT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (DMT)
Description: Placebo for DMT
Study: NCT03041974

Intervention type: PROCEDURE
Intervention: Red Blood Cell transfusion

Intervention type: PROCEDURE
Intervention: Microparticles quantification
Description: Flow cytometric quantification of microparticles in transfused blood
Study: NCT02703064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Furocyst
Description: Furocyst caps BD
Study: NCT00677599

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoid enrichment (cocoa / soy compounds)
Description: Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavonoid enrichment (cocoa / soy compounds)
Description: 27g placebo chocolate bar to be consumed for 365 days.
Study: NCT03693859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement program
Description: The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss + Health Segments
Description: Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
Study: NCT01637948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine mouthrinse
Description: For six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Medicine mouthrinse
Description: six months
Study: NCT02955147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is an anti-inflammatory medication
Study: NCT03573076

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy with Methyl Aminolevulinate creme and red light.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy with Methyl Aminolevulinate creme and red light.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ablative Thulium laser (NAFL)
Description: Non-ablative Thulium laser (NAFL).
Study: NCT03685604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHX disinfection
Description: CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI Disinfection
Description: PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI Disinfection
Description: PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
Study: NCT03573076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative Thulium laser (NAFL)
Description: Non-ablative Thulium laser (NAFL).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency microneedles (RF-MN)
Description: Radio-frequency microneedles (RF-MN).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency microneedles (RF-MN)
Description: Radio-frequency microneedles (RF-MN).
Study: NCT03888157

Intervention type: DRUG
Intervention: Liraglutide
Description: Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
Study: NCT03993600

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)
Description: three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)
Description: three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)
Description: three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects
Study: NCT04411160

Intervention type: DRUG
Intervention: Vitamin C
Description: 4 gram of vitamin c slowly intravenous once daily for 4 days duration.

Intervention type: DRUG
Intervention: Nitric Oxide
Description: nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose

Intervention type: DEVICE
Intervention: ventilators
Description: All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%

Intervention type: DEVICE
Intervention: ventilators
Description: All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
Study: NCT02757690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-dimensional distal pancreatectomy
Description: 3D laparoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-dimensional distal pancreatectomy
Description: 2D laparoscopy
Study: NCT04097353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harvesting Hope for Kids (HH4K)
Description: Weekly meetings at university-based farm

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Surviving Strong for Kids (SS4K)
Description: Enhanced usual care
Study: NCT02675205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel: efficacy and safety in cerebral aneurysm stenting
Study: NCT04179942

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fractional exhaled nitric oxide and CRP levels
Description: measurement of FeNO and Hs-CRP after 3months of CPAP

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Fractional exhaled nitric oxide and CRP levels
Description: measurement of FeNO and Hs-CRP after 3months of CPAP
Study: NCT03003455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation over a bougie
Description: Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nasotracheal Intubation
Description: Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
Study: NCT01044017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: single oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: single oral doses
Study: NCT00673400

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stapled transanal rectum resection
Description: Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
Study: NCT02311231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
Study: NCT02615002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piromelatine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piromelatine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piromelatine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03262142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: Intravenous Piperacillin/tazobactam four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Oral Ciprofloxacin twice daily
Study: NCT02675205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor:efficacy and safety in cerebral aneurysm stenting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study: NCT03818360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an evidence-based smoking cessation intervention comprising brief advice plus active referrals
Description: The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
Study: NCT01877239

Intervention type: OTHER
Intervention: non-intervention
Description: observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
Study: NCT03097081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No orthosis
Description: The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthosis
Description: Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
Study: NCT02237729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: PF-06410293 will be administered as a single 40 mg, subcutaneous dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab-US
Description: Adalimumab-US will be administered as a single 40 mg, subcutaneous dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab-EU
Description: Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
Study: NCT03947307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lymphtaping using Easytape®
Description: lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compression treatment
Description: manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taping
Description: sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
Study: NCT02982824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Oral magnesium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Placebo will be given
Study: NCT02408601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Helioseal - F
Description: Helioseal -F ( Resin based sealant)~1. isolate the tooth surface~2. etch the fissure anatomy with 37% phosphoric acid for 20 seconds~3. wash the tooth surface and dry it. No salivary contamination is accepeted~4. using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~5. light cure the sealant~6. check for high points and the occlusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART sealant
Description: Fuji IX extra strength~1. isolate the tooth surface~2. condition the fissure anatomy using a GC conditioner for 10 seconds~3. wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~4. dry the tooth surface~5. mix the GIC according to the standard powder: liquid ratio~6. place the mix onto the fissures using a plastic spatula~7. apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~8. apply pressure for 10-15 sec and withdraw the finger in a sideways motion~9. scrap out the excess material~10. check for the high points and the occlusion~11. apply petroleum jelly onto the GIC mix~12. advice patient not to eat or drink for 30 minutes.
Study: NCT02527642

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture in buffered media
Description: compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture in buffered media
Description: compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: embryo culture in buffered media
Description: compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: embryo culture in buffered media
Description: compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
Study: NCT00817700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Sleep restriction.
Study: NCT03520101

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAVI_ViV procedure with Edwards valve
Description: The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is \>18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAVI_ViV procedure with CoreValve system
Description: The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
Study: NCT03764527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Two doses a day for 3 days, under supervision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coadministered Artesunate plus Amodiaquine
Description: One dose a day for 3 days, under supervision
Study: NCT01109927

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Insulin
Description: Insulin treatment in accordance to glucose values

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin treatment in accordance to glucose values
Study: NCT04189952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
Study: NCT00535613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: IV, single bolus at completion of anesthetic, 0.1 ml/kg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: IV, single bolus at completion of anesthetic, 0.1 ml/kg